Imagine a blood clot in the brain as a stubborn plug that causes severe damage. This technology creates a special gel that acts like a slow-release sponge, dissolving the clot safely from the inside. It uses tiny particles to keep the medicine stable until it reaches the exact spot where it is needed.
Intracerebral Hemorrhage has no approved pharmacological treatment, leading to a 75% rate of death or severe disability. Current surgical options for deep hematomas are ineffective.
A hydrogel formulation (O2L-001) containing an engineered thrombolytic agent (OptPA) and a manufacturing process for its production.
If you are a biotech drug developer dealing with unstable enzyme delivery — this project developed the NANOp2Lysis platform that stabilizes active enzymes into solid nanoparticles for controlled release.
If you are a surgical equipment manufacturer dealing with the lack of pharmacological options for stroke — this project developed O2L-001, a gel administered via catheter to reduce hematoma volume.
If you are a clinic dealing with the 75% of ICH patients who die or suffer lifelong disability — this project developed a treatment that is easier to administer and safer than the current gold standard.
Based on available project data, specific pricing or cost per dose is not provided.
The project specifically aims to optimize and scale up the manufacturing process for both the drug substance (OptPA) and the drug product (O2L-001).
The treatment is derived from the company's proprietary NANOp2Lysis platform, though specific licensing terms are not detailed in the report.
The project is producing GMP-like batches to support future IMPD/IND submissions and preclinical toxicology studies.
It is designed for a simplified, once-daily local administration via a minimally invasive catheter injection.
The consortium is highly streamlined and industry-focused, consisting of 2 SMEs from France and Belgium. With a 100% industry ratio, the project is geared toward commercialization rather than academic research, leveraging the specialized deep-tech capabilities of Op2Lysis.
Contact Op2Lysis in France regarding the NANOp2Lysis platform
Contact us to explore licensing opportunities for the NANOp2Lysis enzyme stabilization platform.
